150 related articles for article (PubMed ID: 10796063)
1. Gastroduodenal tolerability of medium dose enteric-coated aspirin: a placebo controlled endoscopic study of a new enteric-coated formulation versus regular formulation in healthy volunteers.
Blondon H; Barbier JP; Mahé I; Deverly A; Kolsky H; Bergmann JF
Fundam Clin Pharmacol; 2000; 14(2):155-7. PubMed ID: 10796063
[TBL] [Abstract][Full Text] [Related]
2. Salicylsalicylic acid causes less gastroduodenal mucosal damage than enteric-coated aspirin. An endoscopic comparison.
Scheiman JM; Behler EM; Berardi RR; Elta GH
Dig Dis Sci; 1989 Feb; 34(2):229-32. PubMed ID: 2914543
[TBL] [Abstract][Full Text] [Related]
3. Enteric coating of aspirin significantly decreases gastroduodenal mucosal lesions.
Dammann HG; Burkhardt F; Wolf N
Aliment Pharmacol Ther; 1999 Aug; 13(8):1109-14. PubMed ID: 10468689
[TBL] [Abstract][Full Text] [Related]
4. Gastroduodenal mucosal damage with salsalate versus aspirin: results of experimental models and endoscopic studies in humans.
Scheiman JM; Elta GH
Semin Arthritis Rheum; 1990 Oct; 20(2):121-7. PubMed ID: 2123561
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of regular and enteric-coated aspirin on gastroduodenal mucosa of man.
Hoftiezer JW; Silvoso GR; Burks M; Ivey KJ
Lancet; 1980 Sep; 2(8195 pt 1):609-12. PubMed ID: 6107406
[TBL] [Abstract][Full Text] [Related]
6. Gastro-duodenal mucosal changes associated with low-dose aspirin therapy: a prospective, endoscopic study.
Chowdhury A; Ganguly G; Chowdhury D; Santra A; Gupta JD; Roy T
Indian J Gastroenterol; 2001; 20(6):227-9. PubMed ID: 11817775
[TBL] [Abstract][Full Text] [Related]
7. Gastroduodenal lesions associated with two different piroxicam formulations. An endoscopic comparison.
Aabakken L; Olaussen B; Mowinckel P; Osnes M
Scand J Gastroenterol; 1992 Dec; 27(12):1049-54. PubMed ID: 1475622
[TBL] [Abstract][Full Text] [Related]
8. The effects on gastroduodenal mucosa of a new nonsteroidal anti-inflammatory drug, amtolmetin-guacyl, versus piroxicam in healthy volunteers: a short-term, double-blind, endoscopically controlled study.
Lazzaroni M; Anderloni A; Bianchi Porro G
Eur J Gastroenterol Hepatol; 2001 Jul; 13(7):833-9. PubMed ID: 11474314
[TBL] [Abstract][Full Text] [Related]
9. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa.
Lanza FL; Royer GL; Nelson RS
N Engl J Med; 1980 Jul; 303(3):136-8. PubMed ID: 6966762
[No Abstract] [Full Text] [Related]
10. Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease.
Nema H; Kato M; Katsurada T; Nozaki Y; Yotsukura A; Yoshida I; Sato K; Kawai Y; Takagi Y; Okusa T; Takiguchi S; Sakurai M; Asaka M
J Clin Gastroenterol; 2009 Feb; 43(2):130-2. PubMed ID: 18779739
[TBL] [Abstract][Full Text] [Related]
11. [Endoscopic changes in the stomach and duodenal mucosa caused by microdose acetylsalicylic acid therapy and their prevention--editorial].
Ehrmann J; Procházka V; Konecný M; Spacek M; Urbánek K
Vnitr Lek; 2007 Oct; 53(10):1024-8. PubMed ID: 18072422
[No Abstract] [Full Text] [Related]
12. Aspirin-induced gastric mucosal damage: prevention by enteric-coating and relation to prostaglandin synthesis.
Hawthorne AB; Mahida YR; Cole AT; Hawkey CJ
Br J Clin Pharmacol; 1991 Jul; 32(1):77-83. PubMed ID: 1888645
[TBL] [Abstract][Full Text] [Related]
13. Effects of microencapsulated vs. enteric-coated acetylsalicylic acid on gastric and duodenal mucosa: an endoscopic study.
Malfertheiner P; Stanescu A; Rogatti W; Ditschuneit H
J Clin Gastroenterol; 1988 Jun; 10(3):269-72. PubMed ID: 2980760
[TBL] [Abstract][Full Text] [Related]
14. Effect of allopurinol, sulphasalazine, and vitamin C on aspirin induced gastroduodenal injury in human volunteers.
McAlindon ME; Muller AF; Filipowicz B; Hawkey CJ
Gut; 1996 Apr; 38(4):518-24. PubMed ID: 8707080
[TBL] [Abstract][Full Text] [Related]
15. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
Laine L; Maller ES; Yu C; Quan H; Simon T
Gastroenterology; 2004 Aug; 127(2):395-402. PubMed ID: 15300570
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study.
Fiorucci S; Santucci L; Gresele P; Faccino RM; Del Soldato P; Morelli A
Gastroenterology; 2003 Mar; 124(3):600-7. PubMed ID: 12612897
[TBL] [Abstract][Full Text] [Related]
17. [Gastroduodenal mucosal injuries by aspirine. Management of the risks].
Martínez M JD; Molano V JC; Henao R SC
Rev Gastroenterol Peru; 2016; 36(2):129-34. PubMed ID: 27409089
[TBL] [Abstract][Full Text] [Related]
18. Comparison of effects of calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers.
Murray FE; Hudson N; Atherton JC; Cole AT; Scheck F; Hawkey CJ
Gut; 1996 Jan; 38(1):11-4. PubMed ID: 8566836
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic findings in the stomach and duodenum after treatment with enteric-coated and plain naproxen tablets in healthy subjects.
Oddsson E; Gudjonsson H; Thjodleifsson B
Scand J Gastroenterol; 1990 Mar; 25(3):231-4. PubMed ID: 2181621
[TBL] [Abstract][Full Text] [Related]
20. Interaction of omeprazole with enteric-coated salicylate tablets.
Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
